Regents of the University of Minnesota v. Gilead Sciences, Inc. (Fed. Cir. 2023) | McDonnell Boehnen Hulbert & Berghoff LLP
The Supreme Court's (re)consideration of the enablement requirement expected in its decision later this year in Amgen v. Sanofi may be the most closely watched patent case since AMP v....
Source: jdsupra.com